Vivos Demonstrates that IsoPet™ (RadioGel™) is effective in killing cancer in cats

Richland, WA, May 01, 2018 -- Vivos Inc (OTC: RDGL) announced today the results from the therapy for feline sarcoma.  

Five cats were treated at Washington State University over the course of 15 months for feline sarcoma. The cat patients had advanced disease and relatively large tumor masses.  The objectives of the study were fulfilled. The technique was refined, the dose was optimized and the treatment was effective in the regions where the Y-90 IsoPet was placed without radiation side-effects.

The final report is near completion and the results will be presented at the Annual Meeting of the Society of Nuclear Medicine and Medical Imaging (SNMMI), June 23-26, 2018, Philadelphia, Pennsylvania.

Dr. Mike Korenko, Vivos Inc CEO, stated “We are now confident that IsoPet^TM can be used to effectively treat feline sarcoma. We are sharing these data with the private clinic consortiums.  Our next step is to confirm the effectiveness of IsoPet^TM in treating canine soft tissue sarcoma via testing at the University of Missouri.”  These are positive steps toward demonstrating the effectiveness of this technology as a precision, high-dose therapy for a wide range of cancers.

About Vivos Inc. (OTC: RDGL)

Currently, the Company is engaged in the development of a Yttrium-90 based brachytherapy device, for the treatment of tumors in animals and people. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area.

IsoPet^TM for treating animals uses the same technology RadioGel^TM for treating humans. The Food and Drug Administration advised using different names in order to avoid confusion and cross-use.

IsoPet^TM is a hydrogel liquid containing tiny Yttrium-90 phosphate particles to be injected directly into a tumor. This hydrogel is a liquid at temperatures below body temperature but begins to gel, harden, upon injection as the temperature increases to normal body temperature, thereby locking the particles in place. The particles emit a very high concentrated and contained beta irradiation to kill the tumor. The beta radiation has a short penetration distance so there is minimal collateral damage to healthy tissues outside of the injected area.

IsoPet^TM also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days.  This compares favorably to other available treatment options requiring up to 6 weeks or more to deliver a full course of radiation therapy. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately with no risk to family members.

The IsoPet^TM Solutions division of RDGL is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will begin in the near future.

The Company recently obtained classification clarification from the FDA that they are a device for therapy on skin cancer in animals and they approved our label. No other regulatory approval is required for skin cancer, which is the largest market sector.  RDGL is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of IsoPet^TM to private animal clinic consortiums.

The Company is also engaging the FDA for permission to use RadioGel^TM for the treatment of advanced basal and squamous cell skin cancers in humans.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

CONTACT:

Vivos Inc.
Michael K. Korenko, President & CEO
[email protected]
509-736-4000